ATB Therapeutics is pioneering innovative technologies aimed at addressing cancer and autoimmune diseases through its unique biologic format known as the "atb ody." This new class of biologics is distinguished by its unique composition and novel mechanism of action, which combines multiple targeting and killing domains. The atb ody is designed to enhance effectiveness and safety compared to traditional antibody-drug conjugates, offering increased potency, stability, and superior targeted exposure. This innovative format utilizes an embedded peptide linker that improves in-vivo stability and reduces off-target toxicity, while a full-length antibody with an Fc component enhances blood circulation and cancer cell exposure.

Additionally, ATB Therapeutics employs its proprietary plant-based manufacturing technology, referred to as "atbiofarm," to produce the atb ody in a streamlined, single-step process. This versatile platform not only accelerates development timelines compared to conventional production systems but also has the potential to expand into solid tumors. The atb ody format has shown promising efficacy in both hematological malignancies and solid tumor models, positioning ATB Therapeutics to explore strategic partnerships that could enhance its commercial potential and expedite clinical development.

Belgium

ATB Therapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. 

atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. 

Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. 

The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

ATB Therapeutics

Company Details